55076-60-3

Usage

Uses

Used in Pharmaceutical Industry:
(3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-[(1E)-3-oxo-5-phenyl-1-pentenyl]-2H-cyclopenta[b]furan-2-one is used as a potential pharmaceutical compound for its possible biological activities. The presence of the phenyl group and the benzoyloxy group may contribute to its interaction with biological targets, such as enzymes or receptors, making it a candidate for drug development.
Used in Agrochemical Industry:
In the agrochemical industry, (3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-[(1E)-3-oxo-5-phenyl-1-pentenyl]-2H-cyclopenta[b]furan-2-one may be utilized as a potential active ingredient in pesticides or herbicides. Its complex molecular structure could provide selective targeting of pests or weeds, offering a new approach to crop protection.
Used in Material Science:
(3aR,4R,5R,6aS)-5-(Benzoyloxy)hexahydro-4-[(1E)-3-oxo-5-phenyl-1-pentenyl]-2H-cyclopenta[b]furan-2-one may also find applications in material science due to its unique molecular structure. It could be explored for its potential properties, such as stability, solubility, or reactivity, which may be useful in the development of new materials or coatings.
Further research is necessary to fully understand the properties and potential uses of this chemical compound, as its complex structure may offer novel opportunities in various industries.

InChI:InChI=1/C25H24O5/c26-19(12-11-17-7-3-1-4-8-17)13-14-20-21-15-24(27)29-23(21)16-22(20)30-25(28)18-9-5-2-6-10-18/h1-10,13-14,20-23H,11-12,15-16H2/b14-13+/t20-,21-,22-,23+/m1/s1

Upstream product

• 41162-19-0 dimethyl(2-oxo-4-phenylbutyl)phosphonate 
• 39746-01-5 (1S,5R,6R,7R)-6-formyl-7-benzoyloxy-2-oxabicyclo[3.3.0]octan-3-one 
• 140-10-3 (E)-3-phenylacrylic acid 
• 103-25-3 3-phenylpropanoic acid methyl ester 
• 501-52-0 3-Phenylpropionic acid 
• 40601-45-4 diethyl (2-oxo-4-phenylbutyl)phosphonate 
• 2550-26-7 4-Phenyl-2-butanone 
• 31984-10-8 1-bromo-4-phenylbutan-2-one 
• 1174193-89-5 4-phenyl-1-(1-phenyl-1H-tetrazole-5-sulfonyl)butan-2-one 

Downstream Products

• 41639-74-1 (3aR,4R,5R,6aS)-hexahydro-5-hydroxy-4-[(1E,3S)-5-phenyl-3-hydroxy-(1E)-pentenyl]-2H-cyclopentane [β] furan-2-one 
• 69610-63-5 (3aR,4R,5R,6aS)-hexahydro-4-((3S,E)-5-phenyl-3-(tetrahydro-2H-pyran-2-yloxy)pent-1-enyl)-5-(tetrahydro-2H-pyran-2-yloxy)cyclopenta[b]furan-2-one 
• 856240-62-5 (3aR,4R,5R,6aS)-hexahydro-4-[(1E,3S)-3-hydroxy-5-phenyl-1-penten-1-yl]-2H-cyclopenta[b]furan-2,5-diol 
• 155206-00-1 bimatoprost 
• 55516-35-3 benzoic acid (3aR,4R,5R,6aS)-4-((E)-(R)-3-hydroxy-5-phenyl-pent-1-enyl)-2-oxo-hexahydro-cyclopenta[b]furan-5-yl ester 
• 55444-68-3 (3aR,4R,5R,6aS)-4-[(1E,3S)-3-hydroxy-5-phenylpent-1-en-1-yl]-2-oxo-hexahydro-2H-cyclopenta[b]furan-5-yl benzoate 

Relevant academic research and scientific papers

Preparation method of bemeprost drug intermediate

The invention relates to the technical field of synthesis of medical intermediates, in particular to a preparation method of a bemeprost drug intermediate, which comprises the following steps: by using a compound I as a raw material, reacting with a compound II under the action of alkali to obtain the bemeprost drug intermediate: (3aR, 4R, 5R, 6aS)-5-(benzoyloxy)-hexahydro-4-[(1E)-3oxo-5-phenyl-1-pentenyl]-2H-cyclopenta-[b]-furan-2-ketone. According to the preparation method, the raw materials are easy to obtain, the stereoselectivity is higher, the yield and the purity are higher, and industrial production of the bemeprost drug intermediate is easier.

Novel method for preparing Prostaglandin derivatives

Provided is a novel method for preparing prostaglandin derivatives. The method is suitable for mass production by effectively manufacturing prostaglandin derivatives with high yield. The method comprises the following steps: (S-1) adding a first reducing agent to a prostaglandin intermediate compound represented by chemical formula II and manufacturing a compound represented by chemical formula III; (S-2) manufacturing a compound represented by chemical formula IV from the compound represented by chemical formula III in the presence of a base; (S-3) adding a second reducing agent to the compound represented by chemical formula IV and manufacturing a compound represented by chemical formula V; and (S-4) performing Wittig reaction of the compound represented by chemical formula V and a compound represented by chemical formula VI, and manufacturing a compound represented by chemical formula I.COPYRIGHT KIPO 2017

Improved Process for the Production of Prostaglandins and Prostaglandin Analogs

The present invention relates to an improved process for the production of prostaglandins and prostaglandin analogs. In particular, this invention relates to the production of prostaglandins of the PGF2α-series, including latanoprost, travoprost, and bimatoprost, which are active pharmaceutical ingredients used for the reduction of elevated intraocular pressure in patients with glaucoma and ocular hypertension.

Method for preparing prostaglandin derivative

A method for preparing a prostaglandin derivative represented by the following general formula (I): (wherein Ph represents phenyl group, R1 represents a C1-7 alkyl group, a C1-7 alkenyl group, phenyl group, or benzyl group), which comprises the successive steps (1) to (8) described in the specification, or any one step or two or more successive steps selected from the group consisting of the steps (1) to (8). A method for efficiently, inexpensively and safely preparing prostaglandin derivatives, of which typical example is latanoprost, is provided.

METHOD FOR PREPARING PROSTAGLANDIN DERIVATIVE

A method for preparing a prostaglandin derivative represented by the following general formula (I): (wherein Ph represents phenyl group, R1 represents a C1-7 alkyl group, a C1-7 alkenyl group, phenyl group, or benzyl group), which comprises the successive steps (1) to (8) described in the specification, or any one step or two or more successive steps selected from the group consisting of the steps (1) to (8). A method for efficiently, inexpensively and safely preparing prostaglandin derivatives, of which typical example is latanoprost, is provided.

Process and intermediates to prepare latanoprost

The present invention is a novel intermediate, compound of the formula (VI) and salts thereof. In addition, the invention includes a process for the preparation of a prostaglandin intermediates compounds (IV) and (XVIII) which comprises (1) contacting a the corresponding enone with (-)-chlorodiisopinocampheylborane while maintaining the reaction mixture temperature in the range of from about ?50° to about 0° and (2) contacting the reaction mixture of step (1) with a boron complexing agent.

Process and intermediates to prepare latanoprost

The present invention is a novel intermediate, compound of the formula (VI) and salts thereof. In addition, the invention includes a process for the preparation of a 15(S)-prostaglandin intermediates compounds (IV) and (XVIII) which comprises (1) contacting a the corresponding enone with (-)-chlorodiisopinocampheylborane while maintaining the reaction mixture temperature in the range of from about ?50° to about 0° and (2) contacting the reaction mixture of step (1) with a boron complexing agent.

Synthesis and in vitro evaluation of human FP-receptor selective prostaglandin analogues

The in vitro evaluation of a series of saturated prostaglandins revealed that compounds with omega chin aromatic rings retain nanomolar potency for the human prostaglandin F receptor (hFP receptor), exemplified by compound 8. In contrast, the double bonds are required for activity in the series with an acyclic omega chain as in PGF(2α). (C) 2000 Published by Elsevier Science Ltd.

Novel 11-oxoprostaglandin derivatives

11-Oxoprostaglandin derivatives of the formula STR1 wherein R2 is a hydrogen atom or alkyl of 1-5 carbon atoms, R3 is alkyl of 1-5 carbon atoms, alkylaryl, cycloalkyl of 5-6 ring carbon atoms and a total of 5-10 carbon atoms; benzodi